Corticosteroid‐induced growth hormone secretion in normal and obese subjects
- 1 December 1991
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 35 (6), 485-490
- https://doi.org/10.1111/j.1365-2265.1991.tb00932.x
Abstract
In normal subjects, corticosteroids stimulate growth hormone (GH) secretion at 3 hours. Obesity is associated with blunted GH secretion. In order to clarify both the deranged mechanism of GH secretion in obesity and the corticosteroid mechanism of action we have assessed in normal and obese subjects the effects of dexamethasone, pyridostigmine (a drug capable of suppressing somatostatin release) and GHRH. We also compared in normal subjects the stimulatory effect of three different corticosteroids on plasma GH levels. In both normal and obese subjects the following tests were carried out: placebo; dexamethasone alone (4 mg i.v. at 0 minutes); and dexamethasone plus pyridostigmine (120 mg p.o. at 60 minutes). In normal subjects we also studied the effects of hydrocortisone (100 mg i.v. at 0 minutes) and deflazacort (a corticosteroid that does not cross the blood-brain barrier) (60 mg i.v. at 0 minutes). In obese subjects we also assessed the effect of dexamethasone plus GHRH (100 micrograms i.v. at 150 minutes) on plasma GH levels. Ten normal subjects and 22 obese subjects were studied. Normal controls were within 10% of their ideal body weight. Obese subjects had a body mass index of 37.1 +/- 1.1 (mean +/- SEM). Plasma GH levels were measured by radioimmunoassay. Dexamethasone-induced GH secretion in normal subjects (28.6 +/- 7.8 millimicron/l, P less than 0.05). Corticosteroids did not alter GH levels in obese subjects. Pretreatment with pyridostigmine increased dexamethasone-induced GH release in normal subjects (40.8 +/- 6.8 millimicron/l) but this did not achieve statistical significance. Dexamethasone plus pyridostigmine did not alter GH levels in obese subjects (8.0 +/- 1.6 mU/l). In some subjects, dexamethasone pretreatment potentiated GHRH-stimulated GH secretion, while in half the subjects the basal GH levels were not altered. In control subjects, hydrocortisone and deflazacort caused GH release similar to dexamethasone. Corticosteroids are a new and selective stimulus of GH secretion. They do not cause GH release in obese subjects. Their relative independence from cholinergic control suggest that they act by reducing somatostatin secretion.Keywords
This publication has 26 references indexed in Scilit:
- EFFECT OF ENHANCEMENT OF ENDOGENOUS CHOLINERGIC TONE WITH PYRIDOSTIGMINE ON GROWTH HORMONE (GH) RESPONSES TO GH‐RELEASING HORMONE IN PATIENTS WITH CUSHING'S SYNDROMEClinical Endocrinology, 1990
- GROWTH HORMONE NEUROREGULATION AND ITS ALTERATIONS IN DISEASE STATESClinical Endocrinology, 1988
- GROWTH HORMONE NEUROREGULATION AND ITS ALTERATIONS IN DISEASE STATESClinical Endocrinology, 1988
- GH FEEDBACK OCCURS THROUGH MODULATION OF HYPOTHALAMIC SOMATOSTATIN UNDER CHOLINERGIC CONTROL: STUDIES WITH PYRIDOSTIGMINE AND GHRHClinical Endocrinology, 1987
- The Effect of Enkephalin Analogue on Pituitary Hormone Release in Human ObesityHormone and Metabolic Research, 1987
- GROWTH HORMONE RESPONSE TO LOW DOSE INTRAVENOUS INJECTIONS OF GROWTH HORMONE RELEASING FACTOR IN OBESE AND NORMAL WEIGHT WOMENClinical Endocrinology, 1986
- Impaired Growth Hormone Responses to Growth Hormone–Releasing Factor in ObesityNew England Journal of Medicine, 1984
- Suppression of the Hypothalamo-Pituitary-Adrenal Axis and Growth Hormone Release with DexamethasoneHormone and Metabolic Research, 1971
- Cortisol stimulation of growth hormone production by monkey adenohypophysis in tissue cultureBiochemical and Biophysical Research Communications, 1968
- EFFECT OF CORTICOSTEROIDS ON SERUM GROWTH HORMONEThe Lancet, 1964